中文版
|
English
Hotline：+86 2864841719
Enlai News
Enlai News
CONTACT US
联系我们
Outbound sales&marketing
Contact：Mr. Yang
Tel：+86-28-84871826
Mobile：+86 13908183771
Email：sealinfa@enlaibio.com

Outbound sales&marketing
Contact：Manager Tang
Mobile：+86 18054780191
Email：Amy@enlaibio.com

Outbound sales&marketing
Contact：Manager Yi
Tel：+86-28-84841969
          18980456393
Mobile：+86 18728045915
Email：nero@enlaibio.com

Outbound sales&marketing
Contact：Manager Jiang
Tel：+86-28-64841719
Mobile：+86 17390183901
Email：cynthia@enlaibio.com

Enlai News Your current location: Homepage >Enlai News
请添加图片
First line treatment for chronic lymphocytic leukemia

As a first line treatment drugs for chronic lymphocytic leukemia, Ibrutinib improves survival compared with Ofatumumab in patients with previously treated Chronic Lymphocytic Leukemia.

Can you manufacture other peptides exclusively from your product list?2019-05-17

From Poverty to Harvard Postdoc2013-10-24

What are the acceptable payment methods?2019-05-05

Fingerprints Expose Chemical Identities 2019-01-04

2019 CPHI Shanghai Bio-Pharm Expo 2019-08-18

1/2 上一页 1 2 下一页

Outbound Sales&Marketing

Contact：Mr. Yang  Tel：+86-28-84871826  Mobile：+86 13908183771  Email：sealinfa@enlaibio.com
Contact：Manager Tang  Mobile：+86 18054780191  Email：Amy@enlaibio.com
Contact：Manager Yi  Tel：+86-28-84841969  18980456393  Mobile：+86 18728045915  Email：nero@enlaibio.com
Contact：Manager Jiang  Tel：+86-28-64841719  Mobile：+86 17390183901  Email：cynthia@enlaibio.com
友情链接：

扫码二维码
打开官方网站

扫码二维码
关注官方微信
蜀ICP备10203788号